SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
云端
Lv4
580 积分
2023-09-09 加入
最近求助
最近应助
互助留言
Mechanisms of drug resistance in HCC
5个月前
已完结
Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients
5个月前
已完结
Three ways ChatGPT helps me in my academic writing
5个月前
已完结
Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
5个月前
已完结
A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram
5个月前
已完结
Textbook outcomes of hepatocellular carcinoma patients with sarcopenia: A multicenter analysis
5个月前
已完结
Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study
5个月前
已完结
Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates
6个月前
已关闭
Varying Impact of Lenvatinib or Sorafenib Therapy on Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma
6个月前
已关闭
Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice
7个月前
已完结
没有进行任何应助
已经找到【积分已退回】
6个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论